newsfilter
← Latest News
Business Wire·

Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers, today